23andMe Holding Co. (NASDAQ:ME) Q2 2024 Earnings Call Transcript November 8, 2023 23andMe Holding Co. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.14. Operator: Hello, and welcome to 23andMe’s Fiscal Year 2024 Second Quarter Financial Results Conference Call. As a reminder, this call is being recorded. [Operator Instructions] I would now […]
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Announced launch of new 23andMe+ Total Health™ membership, signed new $20M non-exclusive data license with GSK, continued progress on improving product marginSOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023. Recent Highlights Consumer Increased kit and subscription pricing, seeing b